Company news
Ac Immune Sa (NASDAQ:ACIU) news
Ac Immune Sa news releases on 6ix. Latest, Oct 17, 2023: AC Immune Announces Upcoming Presentations at the 16th CTAD Conference
Press releases — page 2
AC Immune Announces Upcoming Presentations at the 16th CTAD Conference
October 16, 2023
AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023
October 4, 2023
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023
September 4, 2023
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
August 3, 2023
AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023
July 27, 2023
AC Immune SA Appoints New Chief Medical Officer
July 25, 2023
AC Immune Showcasing Precision Medicine Programs at AAIC 2023
July 2, 2023
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease
June 26, 2023
AC Immune Holds Annual General Meeting of Shareholders
June 22, 2023
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update
April 27, 2023
AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease
April 4, 2023
AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline
March 19, 2023
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update
March 15, 2023
AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023
March 7, 2023
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43
February 6, 2023
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial
January 25, 2023
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease
January 17, 2023
AC Immune Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
October 27, 2022
AC Immune Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer’s Disease and Down Syndrome
October 3, 2022
AC Immune Partner LMI Progresses Tau PET Tracer PI-2620 into Late-stage Development in Alzheimer’s Disease
September 25, 2022
AC Immune Receives a Grant from The Michael J. Fox Foundation for Continued Development of Parkinson’s Disease Diagnostic Imaging Agent
August 31, 2022
AC Immune Reports Second Quarter 2022 Financial Results and Provides Corporate Update
July 27, 2022
AC Immune Announces Upcoming Presentations at the Alzheimer’s Association International Conference
July 21, 2022
AC Immune Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease
June 15, 2022
AC Immune Reports First Quarter 2022 Financial Results and Provides Corporate Update
April 27, 2022
AC Immune Reports Changes to Senior Management
April 7, 2022
AC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update
March 21, 2022
AC Immune Reports First Live Images of Alpha-Synuclein in Human Brain with New PET Tracer for Neurodegenerative Disease at AD/PDTM Conference
March 15, 2022
AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer’s Vaccine in High-dose Cohort
February 14, 2022
AC Immune ACI-24 Data in Brain Communications Show Abeta Vaccine-Candidate Induces Immunity Against pyroGlu-Abeta, Key Driver of Alzheimer’s Disease
February 3, 2022
AC Immune Awarded Two Michael J. Fox Foundation Grants to Advance Small Molecule Parkinson’s Disease Programs
December 14, 2021
AC Immune Announces Interim Phase 1b/2a Data Showing that its ACI-35.030 Anti-pTau Alzheimer’s Vaccine Generates a Potent Immune Response
November 11, 2021
AC Immune Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 7, 2021
AC Immune Extends Research Collaboration with University of Pennsylvania Focusing on the Pathogenic Protein TDP-43, a Major Driver of Neurodegenerative Diseases
November 3, 2021
AC Immune Holds its Extraordinary General Meeting and Appoints Monica Shaw, M.D., and Prof. Monika Bütler, Dr. oec., to its Board of Directors
October 28, 2021
AC Immune to Participate in Upcoming Virtual Investor Conferences in September
September 1, 2021
AC Immune Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease
August 30, 2021
AC Immune Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 3, 2021
AC Immune Presents Full Phase 1b Results on Anti-Abeta Vaccine and Discusses its First-in-Class Diagnostic for Parkinson’s Disease at AAIC 2021
July 28, 2021
AC Immune Announces Strategic Acquisition of Industry-leading Parkinson’s Disease Vaccine Candidate and Equity Investment Led by Athos Service GmbH
July 26, 2021
AC Immune acquires AFFiRiS’ Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs targeting neurodegenerative diseases
July 26, 2021
AC Immune Holds its Annual General Meeting of Shareholders
June 24, 2021
AC Immune Provides Update on Alzheimer’s Disease Vaccine Candidates Targeting Pathological Amyloid-Beta
June 1, 2021
AC Immune Announces Expansion of Phase 1b/2a phospho-Tau Alzheimer’s Vaccine Trial and Provides a Program Update
May 16, 2021
AC Immune Reports First Quarter 2021 Financial Results and Provides Corporate Update
April 27, 2021
AC Immune Appoints Experienced Biotech and Investment Executive Dr. Alan Colowick to Board of Directors
March 30, 2021
AC Immune Reports Full-Year 2020 Financial Results and Provides 2021 R&D Outlook
March 22, 2021
AC Immune Announces New Clinical Results in Down Syndrome and Plans for Future Development of Anti-Amyloid-Beta Vaccine
March 15, 2021
AC Immune Presents New Preclinical Data for Therapeutic and Diagnostic Candidates Addressing Novel Targets for Neurodegenerative Diseases
March 8, 2021
AC Immune’s Alzheimer’s Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study
February 10, 2021